EVIDENCE LIBRARY
European Pediatric Palliative Survey Described Midazolam Use and Clinicians’ Views on Sedation
A five-country survey found that midazolam was widely reported in pediatric palliative care. It measured practice reports and attitudes, without directly measuring survival effects.
A five-country survey found that midazolam was widely reported in pediatric palliative care. It measured practice reports and attitudes, without directly measuring survival effects.
What respondents reported
The survey collected responses from 348 physicians. Eighty-five percent reported using midazolam and seventy-eight percent reported opioid use in the relevant care context.
Respondents also addressed palliative sedation and end-of-life decision making. Such answers describe clinicians’ experience and perspectives; they are not the same as audited administration records or prospective patient outcomes.
The limits of a practice survey
The response rate was unknown, and participating clinicians may differ from those who did not participate. Country, specialty, and service differences can affect how terms and practices are understood.
The paper cannot establish that a particular sedative regimen shortened or prolonged a child’s life. For case review, retain indication, symptom burden, treatment goals, dose changes, monitoring, and the documented response. A commonly reported medication remains an exposure requiring clinical context, rather than proof of the intent or effect of an individual administration.
Source paper
Original analysis of the supplied journal article, identified as PMC12532919.